Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-08-16 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于特定股东股份减持计划时间届满并拟继续减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the expiration of a specific shareholder's stock reduction plan and the intention to continue reducing shares. It details the shareholder's holdings, reduction quantities, reduction methods, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about shareholding changes by a specific shareholder, specifically about share reduction plans and their execution. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels and related plans. The document length is 3434 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is MRQ with high confidence.
2019-08-16 Chinese
关于召开2019年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2019 second extraordinary general meeting of shareholders for Xiamen Aide Bio-pharmaceutical Technology Co., Ltd. It includes information about the meeting date, location, agenda items (such as changes in registered capital, amendments to business scope and articles of association), voting procedures (including onsite and online voting), registration details, and proxy forms. The document does not contain financial statements or results but is clearly a formal announcement to shareholders about the upcoming meeting and the proposals to be voted on. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides information and requests votes for meetings. The document length is about 4696 characters, which is substantial and contains detailed meeting and voting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI with high confidence.
2019-07-29 Chinese
中信证券股份有限公司关于公司2019年半年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by CITIC Securities regarding the 2019 half-year fundraising funds deposit and usage status of Xiamen Aide Biomedical Technology Co., Ltd. It details the actual fundraising amount, usage, balance, and management of the funds raised from the IPO, including tables of usage and changes in investment projects. The document references regulatory rules related to fundraising and securities issuance, and includes audit opinions from the sponsor institution. The content is focused on the verification and audit of the use of funds raised in the IPO, not a full annual or interim financial report. It is a specialized audit or verification report on fundraising usage, which fits the category of Audit Report / Information (AR). The document length is over 8000 characters and contains detailed financial data related to fundraising usage, so it is not a mere announcement or certification. Therefore, the best classification is AR (Audit Report / Information). H1 2019
2019-07-29 Chinese
独立董事关于相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on a specific corporate matter related to a capital reduction of a subsidiary. It references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (509 characters) and serves as a formal opinion or announcement rather than a full report. It relates to board-level decisions and governance matters, specifically the independent directors' approval of a board agenda item. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions involving the company's board or senior management.
2019-07-29 Chinese
2019年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2019年半年度报告摘要" which translates to "2019 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses operational highlights, R&D activities, marketing, governance, and accounting policy changes. The length is over 7,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2019
2019-07-29 Chinese
关于变更财务报表格式的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about changes to the format of its financial statements, specifically referencing compliance with new accounting standards issued by the Ministry of Finance in 2019. It details the nature of the changes, the board and supervisory committee approvals, and opinions from independent directors and the supervisory board. The document does not contain actual financial statements or detailed financial data but rather informs stakeholders about the change in reporting format and the approval process. It is a regulatory announcement about accounting policy changes rather than a full financial report or audit report. Given the document length (1840 characters) and content, it fits best as a Regulatory Filing (RNS) rather than an Annual Report, Audit Report, or Interim Report. It is not a report publication announcement since it does not mention the release or availability of a report but rather the change in format and policy.
2019-07-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.